Cost effectiveness of emollients in the prevention of relapses in atopic dermatitis

By Cabout E, Eymere S, Launois R, et al
Published December 20, 2020

Key Takeaways

The present study was conducted to evaluate the cost-effectiveness of different emollients prescribed to atopic dermatitis (AD) patients. Researchers constructed a three-state Markov simulation model over a six-year period with 28 days cycles. They derived the cost and effectiveness data from randomized clinical trials and literature review for the efficacy of treatments, resource utilization and quality of life data, and unit prices from official price lists. In comparison with no treatment, treatment with preventive emollient was a cost-effective option in adult AD patients. The comparative study revealed that emollient A is the most efficient strategy from a willingness to pay £ 200 with a probability of 49%.

Read the full article on Clinical, Cosmetic and Investigational Dermatology.

Share with emailShare to FacebookShare to LinkedInShare to Twitter